[Form 4] Freedom Holding Corp. Insider Trading Activity
Philippe J.R. Vogeleer, a director of Freedom Holding Corp. (FRHC), was awarded and immediately vested 626 restricted shares of the company under the 2019 Equity Incentive Plan on September 15, 2025. The award is recorded as an acquisition at a reported price of $0, reflecting a grant of restricted stock rather than a purchase. Vesting was conditioned on continuous service and market-price performance conditions, and those conditions were satisfied as of the transaction date, leaving Mr. Vogeleer with 626 shares beneficially owned following the transaction.
- Director alignment via equity: The grant vests based on service and market-performance conditions, aligning the director’s interests with shareholders
- Transparent reporting: The Form 4 discloses the grant date, amount (626 shares), vesting conditions, and post-transaction beneficial ownership
- None.
Insights
TL;DR: A director received 626 restricted shares that vested upon satisfying service and market conditions; this is routine executive equity compensation.
The filing documents a compensatory grant of restricted common stock to a board member that vested on the grant date under existing plan terms. The reported price of $0 aligns with equity awards issued as compensation rather than a cash purchase. For governance review, key points are the plan authorization, the existence of market-price vesting conditions, and immediate vesting on the stated date. The size (626 shares) appears modest in isolation; materiality depends on total outstanding shares and the director's overall holdings, which are not disclosed here.
TL;DR: This Form 4 reports a small, vested restricted-share award to a director with no cash consideration—routine and likely immaterial to valuation.
From a securities-disclosure perspective, the form properly reports an acquisition coded as award (A) and shows the post-transaction beneficial ownership. The award’s vesting tied to continuous service and market-price performance is noted, but the filing does not quantify performance targets or disclose total outstanding shares, limiting assessment of dilution or incentive alignment. No derivative instruments or dispositions are reported.